Dupilumab leads to clinical improvements including the acquisition of tolerance to causative foods in non-eosinophilic esophagitis eosinophilic gastrointestinal disorders

HIGHLIGHTS

• who: Naoya Arakawa et al. from the Department of Pediatrics, Gunma University Graduate School of Medicine, Showa-machi, Maebash, Gunma, Japan have published the paper: Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders, in the Journal: Biomolecules 2023, 13, 112. of 27/Dec/2022
• what: The authors report herein the first case of non-EoE EGID that achieved not only symptomatic and histological improvements but also tolerance to the foods responsible for non-EoE EGID following the administration of dupilumab.
• future . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.